Pulmonary Hypertension Trial, Recruiting NCT06331208 Sponsor: Institute for Clinical and Experimental Medicine Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Pulmonary Hypertension Trial, Recruiting

NCT06331208
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Heart Failure group:

  • You are older than 18 years
  • You are willing and able to sign a consent form to participate
  • Your heart's pumping strength (the amount of blood pumped out with each beat) is below 50%
  • You have been diagnosed with heart failure for more than 6 months
  • You are currently taking water pills (a type of medication called a loop diuretic) to manage fluid
  • Your doctor has already recommended a procedure to measure pressures inside your heart (right heart catheterisation)

Control group (people without heart failure):

  • You are older than 18 years
  • You are willing and able to sign a consent form to participate
  • You are a patient at a specific medical centre in Prague (IKEM) attending for a procedure such as closing a small hole in the heart (PFO closure), a heart rhythm treatment (arrhythmia ablation), or a heart pressure measurement — or you are attending for non-invasive tests only

Who may not be able to join:

Heart Failure group:

  • Your heart condition is currently unstable and requires strong medicines to keep it pumping
  • Your kidneys are not working well enough (confirm with trial site for exact level)
  • You have recently had a heart attack or acute coronary event
  • Your heart is pumping too much blood (higher than normal output) (confirm with trial site)
  • You have a type of high blood pressure in the lungs that is not related to heart failure (types I, III, or IV)
  • You currently have an active infection
  • You are having significant difficulty breathing due to a breathing problem
  • You have a large build-up of fluid around your lungs
  • You have a serious lung condition such as treated COPD, asthma, or a known scarring/thickening disease of the lungs

Control group:

  • You have high blood pressure in the lungs, shown on an ultrasound scan of your heart
  • You have had a blood clot in your lungs within the last year
  • An ultrasound of your heart shows that either side of your heart is not pumping properly
  • You have treated asthma, COPD, or a known scarring/thickening disease of the lungs
  • You have significant difficulty doing everyday physical activities due to breathlessness or fatigue (confirm with trial site for exact level)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vojtech Melenovsky, Institute for Clinical and Experimental Medicine

Phone: 420 236055190

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institute for Clinical and Experimental Medicine
Registry
ClinicalTrials.gov
Start date
23 August 2024
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇿 Czechia

Primary endpoints

biomarker of pulmonary vasculopathy in HF; CT characteristics of pulmonary vasculopathy in HF; CT characteristics of presence of heart failure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov